BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20507096)

  • 1. Affinity enhancement pretargeting: synthesis and testing of a 99mTc-labeled bivalent MORF.
    He J; Wang Y; Dou S; Liu X; Zhang S; Liu G; Hnatowich D
    Mol Pharm; 2010 Aug; 7(4):1118-24. PubMed ID: 20507096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.
    Liu G; Dou S; He J; Liu X; Rusckowski M; Hnatowich DJ
    Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):237-46. PubMed ID: 17021815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An improved method for covalently conjugating morpholino oligomers to antitumor antibodies.
    He J; Liu G; Dou S; Gupta S; Rusckowski M; Hnatowich D
    Bioconjug Chem; 2007; 18(3):983-8. PubMed ID: 17385902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affinity enhancement bivalent morpholino for pretargeting: initial evidence by surface plasmon resonance.
    He J; Liu G; Vanderheyden JL; Dou S; Mary R; Hnatowich DJ
    Bioconjug Chem; 2005; 16(2):338-45. PubMed ID: 15769087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake.
    Liu G; He J; Dou S; Gupta S; Vanderheyden JL; Rusckowski M; Hnatowich DJ
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):417-24. PubMed ID: 14691611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector.
    Liu G; Dou S; Pretorius PH; Liu X; Chen L; Rusckowski M; Hnatowich DJ
    Q J Nucl Med Mol Imaging; 2010 Jun; 54(3):333-40. PubMed ID: 20639818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinity enhancement bivalent morpholinos for pretargeting: surface plasmon resonance studies of molecular dimensions.
    He J; Liu X; Zhang S; Liu G; Hnatowich DJ
    Bioconjug Chem; 2005; 16(5):1098-104. PubMed ID: 16173785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor.
    Liu G; He J; Dou S; Gupta S; Rusckowski M; Hnatowich DJ
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1115-23. PubMed ID: 16133391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept.
    He J; Liu G; Gupta S; Zhang Y; Rusckowski M; Hnatowich DJ
    J Nucl Med; 2004 Jun; 45(6):1087-95. PubMed ID: 15181145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigations of 99mTc morpholino pretargeting in mice.
    Liu G; Liu C; Zhang S; He J; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
    Nucl Med Commun; 2003 Jun; 24(6):697-705. PubMed ID: 12766607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog.
    Liu G; Mang'era K; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
    J Nucl Med; 2002 Mar; 43(3):384-91. PubMed ID: 11884499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial investigations of 99mTc-labeled morpholinos for radiopharmaceutical applications.
    Mang'era KO; Liu G; Yi W; Zhang Y; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
    Eur J Nucl Med; 2001 Nov; 28(11):1682-9. PubMed ID: 11702111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting.
    Chen X; Dou S; Liu G; Liu X; Wang Y; Chen L; Rusckowski M; Hnatowich DJ
    Bioconjug Chem; 2008 Aug; 19(8):1518-25. PubMed ID: 18646837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of in vitro and in vivo stability in mice of two morpholino duplexes differing in chain length.
    He J; Liu G; Zhang S; Vanderheyden JL; Liu N; Liu C; Zhang Y; Gupta S; Rusckowski M; Hnatowich DJ
    Bioconjug Chem; 2003; 14(5):1018-23. PubMed ID: 13129406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.
    Liu G; Dou S; Baker S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ
    Cancer Biol Ther; 2010 Oct; 10(8):767-74. PubMed ID: 21099368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF.
    Liu G; Dou S; Pretorius PH; Liu X; Rusckowski M; Hnatowich DJ
    Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):272-80. PubMed ID: 17909792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optical pretargeting of tumor with fluorescent MORF oligomers.
    He J; Rusckowski M; Wang Y; Dou S; Liu X; Zhang S; Liu G; Hnatowich DJ
    Mol Imaging Biol; 2007; 9(1):17-23. PubMed ID: 17171474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector.
    Liu G; Dou S; Rusckowski M; Hnatowich DJ
    Mol Cancer Ther; 2008 May; 7(5):1025-32. PubMed ID: 18483292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacing 99mTc with 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation.
    Liu G; Cheng D; Dou S; Chen X; Liang M; Pretorius PH; Rusckowski M; Hnatowich DJ
    Mol Imaging Biol; 2009; 11(5):303-7. PubMed ID: 19326173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiolabeling morpholinos with 90Y, 111In, 188Re and 99mTc.
    Liu CB; Liu GZ; Liu N; Zhang YM; He J; Rusckowski M; Hnatowich DJ
    Nucl Med Biol; 2003 Feb; 30(2):207-14. PubMed ID: 12623121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.